What does MEDIFAR do?

MEDIFAR is a pharmacy in Izegem. Private Limited, started on 6 November 1985, 1 establishment.

What is the address of MEDIFAR?

The registered office of MEDIFAR is located at Noordkaai 9, 8870 Izegem.

Is MEDIFAR still active?

Yes. According to the CBE (29 October 2026) MEDIFAR is active, legal situation “Normale toestand”, started on 6 November 1985.

Is MEDIFAR registered on Peppol?

Yes, MEDIFAR is registered on the Peppol network with ID 0208:0428055258.

What is the enterprise number of MEDIFAR?

The enterprise number of MEDIFAR is BE0428055258.

When was MEDIFAR founded?

MEDIFAR was founded on 6 November 1985.

Who are the directors of MEDIFAR?

According to the 2025 annual accounts, the directors of MEDIFAR are: Sodiap BV, Alexo BV.

Is MEDIFAR a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 November 1985; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did MEDIFAR make in 2025?

MEDIFAR posted a profit after taxes of € 43,562 in financial year 2025.

What is the revenue of MEDIFAR?

As a small company, MEDIFAR is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 176,068.

How much does an employee at MEDIFAR earn?

The average wage cost per full-time employee at MEDIFAR was € 97,700 in 2025: staff costs of € 97,730 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does MEDIFAR have?

According to the 2025 annual accounts, MEDIFAR has 1 full-time equivalents (FTE).

MEDIFAR (Private Limited) - Izegem - BE0428055258

Dossier MEDIFAR, printed on 29 October 2026 from databakkes.be/en/0428055258/medifar. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

MEDIFAR from Izegem, company number BE0428055258, closed financial year 2025 with a result of € 43,562 after tax. For that financial year MEDIFAR recorded a gross margin of € 176,068 and equity of € 351,857. Compared with financial year 2024, the result moved from € 31,610 to € 43,562. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 12, 2026.

What it is worth Growing

€ 351,857

▲ 14% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 43,562

▲ 38% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 13,191

▼ 23% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 345,657.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 97,730

▲ 6% vs 2024

€ 97,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 7,227

▼ 24% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 121,210

▼ 13% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 17,736

▲ 48% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 158,322 Gross margin 2022: € 158,322 First fiscal year in the series	€ 161,321 Gross margin 2023: € 161,321 ▲ 2% vs 2022 (€ 158,322) Favourable step	€ 149,806 Gross margin 2024: € 149,806 ▼ 7% vs 2023 (€ 161,321) Unfavourable step	€ 176,068 Gross margin 2025: € 176,068 ▲ 18% vs 2024 (€ 149,806) Favourable step	▲ 18%
Profit after taxes	€ 38,967 Profit after taxes 2022: € 38,967 First fiscal year in the series	€ 41,040 Profit after taxes 2023: € 41,040 ▲ 5% vs 2022 (€ 38,967) Favourable step	€ 31,610 Profit after taxes 2024: € 31,610 ▼ 23% vs 2023 (€ 41,040) Unfavourable step	€ 43,562 Profit after taxes 2025: € 43,562 ▲ 38% vs 2024 (€ 31,610) Favourable step	▲ 38%
Equity	€ 591,645 Equity 2022: € 591,645 First fiscal year in the series	€ 276,684 Equity 2023: € 276,684 ▼ 53% vs 2022 (€ 591,645) Unfavourable step	€ 308,295 Equity 2024: € 308,295 ▲ 11% vs 2023 (€ 276,684) Favourable step	€ 351,857 Equity 2025: € 351,857 ▲ 14% vs 2024 (€ 308,295) Favourable step	▲ 14%
Total debts	€ 156,283 Total debts 2022: € 156,283 First fiscal year in the series	€ 164,889 Total debts 2023: € 164,889 ▲ 6% vs 2022 (€ 156,283) Unfavourable step	€ 150,812 Total debts 2024: € 150,812 ▼ 9% vs 2023 (€ 164,889) Favourable step	€ 138,947 Total debts 2025: € 138,947 ▼ 8% vs 2024 (€ 150,812) Favourable step	▼ 8%
Cash	€ 9,760 Cash 2022: € 9,760 First fiscal year in the series	€ 14,241 Cash 2023: € 14,241 ▲ 46% vs 2022 (€ 9,760) Favourable step	€ 17,212 Cash 2024: € 17,212 ▲ 21% vs 2023 (€ 14,241) Favourable step	€ 13,191 Cash 2025: € 13,191 ▼ 23% vs 2024 (€ 17,212) Unfavourable step	▼ 23%
Land & buildings	€ 192,285 Land & buildings 2022: € 192,285 First fiscal year in the series	€ 184,295 Land & buildings 2023: € 184,295 ▼ 4% vs 2022 (€ 192,285) Unchanged	€ 176,305 Land & buildings 2024: € 176,305 ▼ 4% vs 2023 (€ 184,295) Unchanged	€ 168,316 Land & buildings 2025: € 168,316 ▼ 5% vs 2024 (€ 176,305) Unchanged	▼ 5%
Retained profit	€ 585,445 Retained profit 2022: € 585,445 First fiscal year in the series	€ 270,484 Retained profit 2023: € 270,484 ▼ 54% vs 2022 (€ 585,445) Unfavourable step	€ 302,095 Retained profit 2024: € 302,095 ▲ 12% vs 2023 (€ 270,484) Favourable step	€ 345,657 Retained profit 2025: € 345,657 ▲ 14% vs 2024 (€ 302,095) Favourable step	▲ 14%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 356,000 Dividend 2023: € 356,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 356,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 747,927 Balance sheet total 2022: € 747,927 First fiscal year in the series	€ 441,573 Balance sheet total 2023: € 441,573 ▼ 41% vs 2022 (€ 747,927) Unchanged	€ 459,107 Balance sheet total 2024: € 459,107 ▲ 4% vs 2023 (€ 441,573) Unchanged	€ 490,803 Balance sheet total 2025: € 490,803 ▲ 7% vs 2024 (€ 459,107) Unchanged	▲ 7%
Employees (FTE)	2.5 Employees (FTE) 2022: 2.5 First fiscal year in the series	1 Employees (FTE) 2023: 1 ▼ 1.5 vs 2022 (2.5) Unchanged	1 Employees (FTE) 2024: 1 Unchanged (1) Unchanged	1 Employees (FTE) 2025: 1 Unchanged (1) Unchanged

Key figures of MEDIFAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MEDIFAR?

What happened at MEDIFAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 12, 2026 New annual accounts for financial year 2025: profit of € 43,562 (▲ 38% vs 2024). Source: NBB ↗
2022 Alexo BV became a director. NBB
2020 Sodiap BV became a director. NBB
Nov 6, 1985 New establishment in Mons. KBO
Nov 6, 1985 Start of the company according to the CBE. KBO

In short

From € 38,967 profit in 2022 to € 43,562 profit in 2025.

Paid € 53,862 in corporate taxes since 2022.

Best year ever: 2025, with € 43,562 profit.

On average € 176,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

SODIAP 100%

The stake of SODIAP comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

MEDIFAR

Behind MEDIFAR are Sodiap BV and Alexo BV. The shares are held by SODIAP (100%).

Directors

According to the 2025 annual accounts

Sodiap BV

Managing director · represented by Tom Goderis

Also active at: SDC, HC Pharma, APOTHEEK JENNE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT, C.E. FARMA, SANIFAR +24 more

since 2020

Alexo BV

Chairman of the board · represented by Olivier Delaere

Also active at: SDC, HC Pharma, SODIAP, APOTHEEK JENNE, PANNOC CHEMIE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT +34 more

since 2022

Shareholders

SODIAP

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Noordkaai 9

8870 Izegem

2.206.769.596

Place de Cuesmes (C.) 7

7033 Mons

Active since 6 November 1985

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

SDC same network

€ -2,508 gross margin · 2025

SODIAP same network

€ 5.3 million revenue · 2025

Apotheek de Lisseweg same network

€ 53,881 gross margin · 2025

GANDAFAR same network

€ 253,436 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0428.055.258

VAT number

BE 0428.055.258

Registered office

Noordkaai 9, 8870 Izegem

Names & denominations

MEDIFAR

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

6 November 1985

Peppol

Active · Active since 6 Jun 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

MEDIFAR

Financials

What happened to MEDIFAR?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions